Results showed that IRs of MACE and MI per 100 person-years increased corresponding with the patient’s 10-year ASCVD risk score. 2,3 However, a substantially significant increase was seen among those ...

Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its ...

While low-density lipoprotein (LDL) particles are much more abundant than lipoprotein(a) [Lp(a)] particles and carry the greatest overall risk for coronary heart disease (CHD), on a per-particle basis ...

Lipoprotein(a) levels, which are largely determined by genetics, appear to fluctuate over time, particularly in individuals with moderately elevated concentrations, a UK Biobank analysis shows. People ...

Even after stopping treatment with the novel small interfering RNA (siRNA) olpasiran (Amgen), patients experience sustained lowering of lipoprotein(a) for almost 1 year, according to new phase II data ...

Baseline lipoprotein a, or Lp(a), levels are strongly associated with major adverse cardiovascular events (MACE) in high-risk patients with elevated triglyceride levels receiving statin therapy, a new ...

Please provide your email address to receive an email when new articles are posted on . About 20% of the global population and one in five U.S. adults have elevated levels of lipoprotein(a), a complex ...